Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : Laxxon Medical
Deal Size : Undisclosed
Deal Type : Partnership
Adare Pharma, Laxxon Partner to Advance 3D Printed Oral Dosage Forms
Details : The partnership aims to leverage Adare's state-of-the-art cGMP facilities and Laxxon's innovative 3D printing technology to bring innovative new oral dosage forms to market.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 18, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : Laxxon Medical
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Recipient : Ellodi Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ellodi Pharmaceuticals is dedicated to the clinical development of APT-1011, a novel therapy in Phase 3 development for the treatment of Eosinophilic Esophagitis (EoE) spun-out of Adare Pharmaceuticals (Adare).
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
September 22, 2020
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Recipient : Ellodi Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mazindol
Therapeutic Area : Sleep
Study Phase : Phase II
Sponsor : NLS Pharmaceutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : NLS Pharmaceutics entered a collaboration to develop mazindol (MZD) CR product candidates for the treatment of narcolepsy and ADHD utilizing Adare’s proprietary modified release technologies.
Product Name : Quilience
Product Type : Controlled Substance
Upfront Cash : Undisclosed
January 13, 2020
Lead Product(s) : Mazindol
Therapeutic Area : Sleep
Highest Development Status : Phase II
Sponsor : NLS Pharmaceutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : APT-1011
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
June 19, 2017
Lead Product(s) : APT-1011
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable